Will INBX Continue Burning Cash While Markets Price In Miracles That Haven't Arrived?

Inhibrx Biosciences (NASDAQ: INBX) reports first-quarter 2026 earnings tomorrow, May 13, with the clinical-stage biotech facing heightened scrutiny after a volatile year that saw shares surge over 900%. The central question: can the company's pipeline progress—particularly its lead regenerative medicine candidate INBRX-109—justify a valuation that has ballooned to $1.88 billion despite minimal revenue, or will investors confront the reality of widening losses and an extended path to profitability?

Part 1: Earnings Preview

Inhibrx Biosciences is a clinical-stage biotechnology company focused on developing next-generation protein therapeutics using proprietary engineering platforms, with lead programs targeting tissue regeneration (INBRX-109) and oncology (INBRX-106). The company's modular approach enables the design of multispecific and multivalent biologics aimed at challenging targets in areas of high unmet medical need.

Inhibrx is expected to report Q1 2026 results on May 13, with the consensus estimate calling for a loss of $2.37 per share. The company most recently reported Q4 2025 earnings of -$2.11 per share on March 19. Comparing to the same quarter last year, the Q1 2026 estimate of -$2.37 represents a 15.36% improvement from the prior-year loss of -$2.80, though losses remain substantial as the company advances its clinical programs.

Three key themes define this earnings story:

Clinical Milestone Execution: Investors will scrutinize any updates on INBRX-109's Phase 2 trial in tissue repair and regeneration, particularly enrollment progress and preliminary safety data. Recent analyst upgrades from Stifel Nicolaus (initiating coverage with a $150 price target) and Lifesci Capital (raising to "strong-buy") reflect optimism around the platform's potential, but tangible clinical progress is essential to sustain the stock's momentum after its extraordinary 965% one-year gain.

Cash Runway and Burn Rate: With a debt-to-equity ratio of 13.39 and negative operating cash flow, the company's financial sustainability is paramount. Analysts will focus on quarterly cash burn, remaining runway, and management's guidance on funding needs—particularly whether the current $1.88 billion market cap provides sufficient currency for non-dilutive financing or strategic partnerships.

Revenue Trajectory and Partnership Potential: While Inhibrx generated just $1.3 million in revenue over the trailing twelve months, any commentary on potential licensing deals, collaboration agreements, or milestone payments could significantly impact sentiment. The company's proprietary protein engineering platforms may attract pharma partners seeking differentiated biologics, and hints of such discussions would provide validation beyond clinical data alone.

Ahead of the release, Wall Street sentiment has improved notably. The analyst consensus has shifted to 2 Strong Buys and 2 Holds (no sells), with the average price target of $250 implying 130% upside from current levels. However, this optimism must be weighed against the reality that only one analyst is providing formal EPS estimates, suggesting limited Street coverage for a company of this valuation. Stifel's recent initiation emphasized the "differentiated mechanism" of INBRX-109, while the upgrade to strong-buy from Lifesci Capital signals growing conviction in the pipeline's commercial potential.

Part 2: Historical Earnings Performance

Inhibrx Biosciences has demonstrated an inconsistent earnings track record over the past four quarters, with two beats and two misses against analyst estimates. In Q2 2025, the company delivered a significant positive surprise, reporting -$1.85 per share versus the -$2.92 consensus—a 36.64% beat that reflected better-than-expected expense management. However, the most recent quarter (Q4 2025) saw a modest miss, with actual EPS of -$2.11 coming in $0.03 worse than the -$2.08 estimate, representing a -9.80% negative surprise.

The pattern reveals a company navigating the unpredictable cash burn dynamics typical of clinical-stage biotechs. Q1 2025 also missed estimates by -9.80% (-$2.80 actual vs. -$2.55 expected), while Q3 2025 had no consensus estimate for comparison. The lack of consistent analyst coverage—evidenced by "N/A" estimates in two of the past four quarters—underscores the challenge investors face in modeling this name. Losses have ranged from -$1.85 to -$2.80 per share over the trailing year, with no clear trend toward improvement, as the company continues investing heavily in clinical development ahead of potential commercialization milestones.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Inhibrx Biosciences typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's initial reaction to the actual numbers.

Historical price behavior around Inhibrx earnings reveals significant volatility, with an average absolute Day 0 move of 4.55% and Day +1 move of 3.54%. However, these averages mask extreme variability—the stock has experienced Day 0 swings ranging from -7.25% to +7.53%, and Day +1 moves spanning from -6.09% to +10.89%. The most dramatic recent reaction came in March 2026, when shares fell 5.56% on earnings day and extended losses to -6.09% the following session, reflecting disappointment with the Q4 miss and cautious guidance.

Notably, the stock's post-earnings behavior has become more pronounced as its market cap has grown. The August 2024 earnings saw minimal movement (0.44% Day 0, -0.09% Day +1), while more recent reports have triggered double-digit intraday ranges—the November 2025 release produced a 15.01% Day 0 range despite ultimately closing up just 6.04%. This pattern suggests that as institutional ownership and options activity have increased, earnings have become higher-stakes events with amplified short-term volatility. Investors should prepare for potential swings of 5-10% in either direction based on how results and guidance compare to the Street's -$2.37 EPS expectation.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 7.98% for the May 15 expiration, which sits above the historical average Day 0 move of 4.55% but below the average Day +1 move of 3.54% when considering cumulative two-day volatility. This suggests options traders are anticipating a more significant reaction than the typical single-day move, aligning with the stock's recent pattern of elevated post-earnings volatility as its profile has grown.

Part 3: What Analysts Are Saying

Wall Street maintains a cautiously optimistic stance on Inhibrx Biosciences, with the consensus rating at 4.00 (Buy) based on 2 Strong Buy recommendations and 2 Hold ratings—notably, there are zero sell-side ratings. The average price target of $250 implies substantial upside of 130% from the current price of $108.65, with estimates ranging from a low of $200 to a high of $300. This wide target range reflects both the significant potential upside if clinical programs succeed and the inherent uncertainty in valuing a pre-revenue biotech.

Sentiment has improved over the past month, with the consensus rating rising from 3.67 to 4.00 as one analyst upgraded their stance to Strong Buy. This shift followed Stifel Nicolaus's April initiation of coverage with a Buy rating and $150 target, citing the "differentiated mechanism of action" for INBRX-109, and Lifesci Capital's upgrade to Strong Buy in late April. The recent wave of positive analyst actions suggests growing Street conviction that the company's protein engineering platforms can deliver meaningful clinical and commercial outcomes, though the limited number of covering analysts (just four firms) indicates this remains a relatively under-followed story despite its $1.88 billion market cap.

Part 4: Technical Picture

Inhibrx Biosciences enters earnings with a Buy signal at 88% on the Barchart Technical Opinion, down slightly from 100% last week but significantly improved from 56% a month ago. This reflects strong recent momentum that has carried shares from the low-$60s in January to the current $108.65, though the modest weekly pullback suggests some near-term consolidation after the stock's extraordinary run.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum remains positive but has cooled from recent extremes, consistent with the stock trading below its 5-day and 10-day moving averages
• Medium-term (100% Buy): Strong buy signal confirms the intermediate-term uptrend remains firmly intact as the stock holds well above its 50-day moving average
• Long-term (100% Buy): Powerful buy signal reflects the stock's position 67% above its 200-day moving average, underscoring the strength of the multi-month rally

Trend Characteristics: The Strong strength rating combined with Average direction suggests a robust uptrend that has entered a period of digestion rather than reversal—a constructive setup heading into a potentially volatile earnings event.

The stock is currently trading at $108.65, positioned below both its 5-day moving average of $127.39 and 10-day moving average of $127.58, indicating short-term weakness after peaking near $155 in late April. However, INBX remains above all longer-term moving averages—the 20-day ($116.17), 50-day ($87.63), 100-day ($83.01), and 200-day ($65.20)—confirming the broader uptrend is intact despite recent consolidation. The 20-day moving average at $116.17 represents immediate resistance, while the 50-day at $87.63 would serve as critical support if the stock were to sell off on disappointing results. The technical setup is moderately supportive: the pullback from recent highs has relieved overbought conditions without breaking the uptrend structure, giving the stock room to move in either direction based on the substance of tomorrow's report and management's commentary on clinical progress and cash runway.